Integra LifeSciences Expects FY24 Revenue of $1.609B-$1.629B (Prior $1.672B-$1.687B) Vs $1.676B Est, Adj EPS of $2.41-$2.57 (Prior $3.01-$3.11) Vs $3.04 Est
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences has updated its FY24 revenue and adjusted EPS expectations to $1.609B-$1.629B and $2.41-$2.57, respectively, down from prior estimates. The revised outlook reflects quality and compliance issues and significant investments in improvements.
July 29, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra LifeSciences has revised its FY24 revenue and adjusted EPS expectations downward due to quality and compliance issues and significant investments in improvements. The new revenue range is $1.609B-$1.629B, and adjusted EPS is $2.41-$2.57.
The downward revision in revenue and adjusted EPS expectations indicates potential challenges for Integra LifeSciences, likely leading to a negative short-term impact on the stock price. The issues with quality and compliance, along with significant investments in improvements, suggest operational difficulties that may concern investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100